There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK – Research Report), Aldeyra Therapeutics (ALDX – Research Report) and Pliant Therapeutics (PLRX – Research Report) with bullish sentiments.
Cytokinetics (CYTK)
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Cytokinetics, with a price target of $80.00. The company’s shares closed last Thursday at $36.86.
According to TipRanks.com, Syed has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -11.2% and a 37.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.
Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $61.31, a 56.7% upside from current levels. In a report issued on February 28, Raymond James also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
Aldeyra Therapeutics (ALDX)
In a report released yesterday, Justin Kim from Oppenheimer maintained a Buy rating on Aldeyra Therapeutics, with a price target of $13.00. The company’s shares closed last Thursday at $7.90, close to its 52-week high of $7.99.
According to TipRanks.com, Kim is a 4-star analyst with an average return of 14.5% and a 50.5% success rate. Kim covers the Healthcare sector, focusing on stocks such as Chinook Therapeutics, Immunocore Holdings, and Cytokinetics.
Currently, the analyst consensus on Aldeyra Therapeutics is a Strong Buy with an average price target of $21.25, which is a 173.5% upside from current levels. In a report issued on February 23, BTIG also maintained a Buy rating on the stock with a $29.00 price target.
Pliant Therapeutics (PLRX)
Oppenheimer analyst Jeff Jones reiterated a Buy rating on Pliant Therapeutics yesterday and set a price target of $44.00. The company’s shares closed last Thursday at $28.57.
According to TipRanks.com, Jones is a 4-star analyst with an average return of 9.7% and a 51.4% success rate. Jones covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Prometheus Biosciences, and Ventyx Biosciences.
Pliant Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $49.78, a 58.3% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $51.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYTK: